HRP20191732T1 - Terapijska modulacija lubrikacije okularne površine - Google Patents
Terapijska modulacija lubrikacije okularne površine Download PDFInfo
- Publication number
- HRP20191732T1 HRP20191732T1 HRP20191732T HRP20191732T1 HR P20191732 T1 HRP20191732 T1 HR P20191732T1 HR P20191732 T HRP20191732 T HR P20191732T HR P20191732 T1 HRP20191732 T1 HR P20191732T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- use according
- prg4
- group
- androgen
- Prior art date
Links
- 238000005461 lubrication Methods 0.000 title claims 6
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 101001123332 Homo sapiens Proteoglycan 4 Proteins 0.000 claims 9
- 102100028965 Proteoglycan 4 Human genes 0.000 claims 9
- 239000003098 androgen Substances 0.000 claims 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 230000001965 increasing effect Effects 0.000 claims 3
- 239000000849 selective androgen receptor modulator Substances 0.000 claims 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
- 229940083324 Selective androgen receptor modulator Drugs 0.000 claims 2
- 229920002125 Sokalan® Polymers 0.000 claims 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003974 emollient agent Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000014759 maintenance of location Effects 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- YVXVTLGIDOACBJ-SFHVURJKSA-N (2S)-3-(4-acetamidophenoxy)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide Chemical compound C1=CC(NC(=O)C)=CC=C1OC[C@](C)(O)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 YVXVTLGIDOACBJ-SFHVURJKSA-N 0.000 claims 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 claims 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 1
- 206010002261 Androgen deficiency Diseases 0.000 claims 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 claims 1
- QSLJIVKCVHQPLV-PEMPUTJUSA-N Oxandrin Chemical compound C([C@@H]1CC2)C(=O)OC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 QSLJIVKCVHQPLV-PEMPUTJUSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 229920000148 Polycarbophil calcium Polymers 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
- 229920002385 Sodium hyaluronate Polymers 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229940030486 androgens Drugs 0.000 claims 1
- 239000003212 astringent agent Substances 0.000 claims 1
- 239000003855 balanced salt solution Substances 0.000 claims 1
- 239000008366 buffered solution Substances 0.000 claims 1
- 239000001110 calcium chloride Substances 0.000 claims 1
- 229910001628 calcium chloride Inorganic materials 0.000 claims 1
- 229960001631 carbomer Drugs 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 230000008020 evaporation Effects 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229910001629 magnesium chloride Inorganic materials 0.000 claims 1
- 210000004175 meibomian gland Anatomy 0.000 claims 1
- 229960004719 nandrolone Drugs 0.000 claims 1
- NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims 1
- 229920002401 polyacrylamide Polymers 0.000 claims 1
- 229950005134 polycarbophil Drugs 0.000 claims 1
- 239000004926 polymethyl methacrylate Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 239000011736 potassium bicarbonate Substances 0.000 claims 1
- 235000015497 potassium bicarbonate Nutrition 0.000 claims 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims 1
- 239000001103 potassium chloride Substances 0.000 claims 1
- 235000011164 potassium chloride Nutrition 0.000 claims 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 229940080818 propionamide Drugs 0.000 claims 1
- 239000000661 sodium alginate Substances 0.000 claims 1
- 235000010413 sodium alginate Nutrition 0.000 claims 1
- 229940005550 sodium alginate Drugs 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- 229940010747 sodium hyaluronate Drugs 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229960003604 testosterone Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims 1
- 229940038773 trisodium citrate Drugs 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
- 239000005526 vasoconstrictor agent Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Materials For Medical Uses (AREA)
- Eyeglasses (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Claims (15)
1. Farmaceutska kompozicija za primjenu u liječenju nedostatka okularne lubrikacije ili simptoma udruženih sa njim koja sadrži PRG4 ili njegov fragment za lubrikaciju u kombinaciji sa terapijski efikasnom koncentracijom PRG4-inducirajućeg spoja odabranog iz grupe koja se sastoji od androgena, selektivnog modulatora receptora androgena, i analoga androgena, pri čemu navedeni analog androgena je odabran iz grupe koja se sastoji od 17α-metil-17β-hidroksi-2-oksa-5α-androstan-3-ona, 4,5α-dihidrotestosterona, i 19-nortestosterona, pri čemu navedeno liječenje obuhvaća topikalnu administraciju navedenog spoja na okularnu površinu.
2. Farmaceutska kompozicija za primjenu prema patentnom zahtjevu 1, pri čemu nedostatak okularne lubrikacije je neželjena okularna granična lubrikacija koja nastaje od bolesti suhog oka uslijed nedostatka vodenog filma ili isparavanja, Sjögren-ovog sindroma, keratoconjunctivitis sicca, nedostatka androgena, bolesti meibomian žlijezda, zamjenske terapije estrogena, nošenja kontaktnih leća, refraktivne operacije, smanjenog vremena prekida suznog filma, alergije, poremećaja okularne površine, povećanih nivoa proteaze u suznom filmu i na okularnoj površini, kronične inflamacije, hiperosmolarnosti ili starenja.
3. Farmaceutska kompozicija za primjenu prema patentnom zahtjevu 1, pri čemu selektivni modulator receptora androgena je odabran iz grupe koja se sastoji od aril-propionamidskog spoja odabranog iz grupe koja se sastoji od S-3-(4-acetilamino-fenoksi)-2-hidroksi-2-metil-N-(4-nitro-3-trifluorometil-fenil)-propionamida [S4], i S-3-(4-fluorofenoksi)-2-hidroksi-2-metil-N-(4-nitro-3-trifluorometil-fenil)-propionamida [S-1]).
4. Farmaceutska kompozicija za primjenu prema patentnim zahtjevima 1 ili 2 pri čemu navedeni androgen je testosteron.
5. Farmaceutska kompozicija za primjenu prema bilo kojem od patentnih zahtjeva 1 do 4, pri čemu kompozicija sadrži 10-10,000 µg/mL PRG4.
6. Farmaceutska kompozicija za primjenu prema bilo kojem od patentnih zahtjeva 1 do 5, pri čemu kompozicija sadrži 50-500 µg/mL PRG4.
7. Farmaceutska kompozicija za primjenu prema patentnom zahtjevu 1, pri čemu kompozicija sadrži 0.0001-0.1% m/v androgena, analoga androgena, ili selektivnog modulatora receptora androgena.
8. Farmaceutska kompozicija za primjenu prema bilo kojem od patentnih zahtjeva 1 do 6, pri čemu PRG4 ima prosječnu molarnu masu između 50 kDa i 400kDa sadržavajući jedan ili više fragmenata za lubrikaciju.
9. Farmaceutska kompozicija za primjenu prema bilo kojem od patentnih zahtjeva 1 do 6, pri čemu PRG4 je rekombinantni ili izolirani polipeptid.
10. Farmaceutska kompozicija za primjenu prema bilo kojem od patentnih zahtjeva 1 do 6, pri čemu PRG4 je izolirani aminokiselinski homolog sa aminokiselinskom sekvencom koja je najmanje 75% identična sa SEQ ID NO. 1 (SEK ID BR. 1).
11. Farmaceutska kompozicija za primjenu prema patentnom zahtjevu 1, koja dalje sadrži natrij hijaluronat ili hijaluronsku kiselinu u terapijski efikasnoj koncentraciji od 10-100,000 µg/mL.
12. Farmaceutska kompozicija za primjenu prema patentnom zahtjevu 1, koja dalje sadrži jedan ili više površinski aktivnih fosfolipida odabranih iz grupe koja se sastoji od L-α-dipalmitoilfosfatidilholina, fosfatidilholina, fosfatidil-etanolamina i sfinogomijelina u terapijski efikasnoj koncentraciji od 10-10,000 µg/mL.
13. Farmaceutska kompozicija za primjenu prema patentnom zahtjevu 1, koja dalje sadrži fosfatom puferiranu otopinu natrij-klorida u vodi, ili oftalmički prihvatljivu balansiranu otopinu soli koji sadrži terapijski efikasnu koncentraciju jednog ili više elektrolita odabranih iz grupe koja se sastoji od natrij fosfata, natrij klorida, kalij klorida, natrij bikarbonata, kalij bikarbonata, kalcij klorida, magnezij klorida, trinatrij citrata, klorovodične kiseline, i natrij hidroksida.
14. Farmaceutska kompozicija za primjenu prema patentnom zahtjevu 1, koja dalje sadrži terapijski efikasnu koncentraciju jednog ili više oftalmičkih ublaživača, ekscipijenasa, astringenasa, vazokonstriktora, emolijenasa, ili agens za povećavanje vremena zadržavanja, pri čemu po izboru agens za povećanje vremena zadržavanja je odabran iz grupe koja se sastoji od hidroksipropilmetilceluloze, karboksimetilceluloze, karbomera, polimera akrilne kiseline, polimetilmetakrilata, poliakrilamida, polikarbofila, polietilen oksida, akrilna kiselina/butil akrilat kopolimera, natrij alginata, dekstrana, ili njihovu kombinaciju.
15. Farmaceutska kompozicija za primjenu prema bilo kojem od patentnih zahtjeva 1 do 13, pri čemu kompozicija sadrži 100-300 µg/mL PRG4 i 0.0001-0.1% m/v navedenog PRG4-inducirajućeg spoja.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5111208P | 2008-05-07 | 2008-05-07 | |
EP09743588.7A EP2276496B1 (en) | 2008-05-07 | 2009-05-06 | Therapeutic modulation of ocular surface lubrication |
PCT/US2009/043015 WO2009137602A1 (en) | 2008-05-07 | 2009-05-06 | Therapeutic modulation of ocular surface lubrication |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20191732T1 true HRP20191732T1 (hr) | 2019-12-13 |
Family
ID=41264988
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20150097AT HRP20150097T1 (hr) | 2008-05-07 | 2015-01-26 | Terapijska nadopuna i poboljšanje vlaženja površine oka |
HRP20171079TT HRP20171079T1 (hr) | 2008-05-07 | 2017-07-13 | Terapijska nadopuna i poboljšanje vlaženja površine oka |
HRP20191732 HRP20191732T1 (hr) | 2008-05-07 | 2019-09-25 | Terapijska modulacija lubrikacije okularne površine |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20150097AT HRP20150097T1 (hr) | 2008-05-07 | 2015-01-26 | Terapijska nadopuna i poboljšanje vlaženja površine oka |
HRP20171079TT HRP20171079T1 (hr) | 2008-05-07 | 2017-07-13 | Terapijska nadopuna i poboljšanje vlaženja površine oka |
Country Status (16)
Country | Link |
---|---|
US (9) | US9393285B2 (hr) |
EP (4) | EP2285364B1 (hr) |
JP (3) | JP5508398B2 (hr) |
CN (2) | CN102164593B (hr) |
CA (3) | CA2722913C (hr) |
CY (2) | CY1119122T1 (hr) |
DK (3) | DK2285364T3 (hr) |
ES (3) | ES2530723T3 (hr) |
HR (3) | HRP20150097T1 (hr) |
HU (2) | HUE024146T2 (hr) |
LT (2) | LT2915529T (hr) |
PL (3) | PL2285364T3 (hr) |
PT (2) | PT2915529T (hr) |
RU (1) | RU2510274C2 (hr) |
SI (3) | SI2915529T1 (hr) |
WO (3) | WO2009137217A2 (hr) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040082509A1 (en) | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
US20070016256A1 (en) * | 2005-07-18 | 2007-01-18 | Korb Donald R | Method and apparatus for treating gland dysfunction |
US8950405B2 (en) | 2006-05-15 | 2015-02-10 | Tearscience, Inc. | Treatment of obstructive disorders of the eye or eyelid |
US20090043365A1 (en) * | 2005-07-18 | 2009-02-12 | Kolis Scientific, Inc. | Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma |
WO2013003594A2 (en) | 2011-06-28 | 2013-01-03 | Tearscience, Inc. | Methods and systems for treating meibomian gland dysfunction using radio-frequency energy |
US20070060988A1 (en) | 2005-07-18 | 2007-03-15 | Grenon Stephen M | Melting meibomian gland obstructions |
US7981145B2 (en) | 2005-07-18 | 2011-07-19 | Tearscience Inc. | Treatment of meibomian glands |
US20080114423A1 (en) | 2006-05-15 | 2008-05-15 | Grenon Stephen M | Apparatus for inner eyelid treatment of meibomian gland dysfunction |
US7981146B2 (en) | 2006-05-15 | 2011-07-19 | Tearscience Inc. | Inner eyelid treatment for treating meibomian gland dysfunction |
US7981095B2 (en) * | 2005-07-18 | 2011-07-19 | Tearscience, Inc. | Methods for treating meibomian gland dysfunction employing fluid jet |
WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
US8128673B2 (en) | 2006-05-15 | 2012-03-06 | Tearscience, Inc. | System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction |
US7976573B2 (en) | 2006-05-15 | 2011-07-12 | Tearscience, Inc. | Inner eyelid heat and pressure treatment for treating meibomian gland dysfunction |
US8128674B2 (en) | 2006-05-15 | 2012-03-06 | Tearscience, Inc. | System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction |
US7981147B2 (en) | 2006-05-15 | 2011-07-19 | Tearscience, Inc. | Outer eyelid heat and pressure treatment for treating meibomian gland dysfunction |
US8137390B2 (en) | 2006-05-15 | 2012-03-20 | Tearscience, Inc. | System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction |
US9314369B2 (en) | 2006-05-15 | 2016-04-19 | Tearscience, Inc. | System for inner eyelid treatment of meibomian gland dysfunction |
US8007524B2 (en) | 2006-05-15 | 2011-08-30 | Tearscience, Inc. | Heat treatment and heat loss reduction for treating meibomian gland dysfunction |
US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
US8506944B2 (en) * | 2008-05-07 | 2013-08-13 | The Regents Of The University Of California | Replenishment and enrichment of ocular surface lubrication |
RU2510274C2 (ru) * | 2008-05-07 | 2014-03-27 | Дзе Реджентс Оф Дзе Юниверсити Оф Калифорния | Терапевтическое восстановление и усиление увлажнения поверхности глаза |
WO2009143864A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
WO2009143865A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
CA3110817C (en) | 2009-05-22 | 2023-08-15 | Lubris, Llc | Application and uses of prg4 and therapeutic modulation thereof |
JP2013516501A (ja) * | 2010-01-11 | 2013-05-13 | ジーティーエックス・インコーポレイテッド | マイボーム腺機能障害を治療する方法 |
WO2011160653A1 (en) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
US9150618B2 (en) | 2010-10-14 | 2015-10-06 | Xigen Inflammation Ltd. | Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
WO2012174123A1 (en) * | 2011-06-13 | 2012-12-20 | Allergan, Inc. | Treatment of psychological trauma |
ES2780182T3 (es) * | 2011-06-29 | 2020-08-24 | Allergan Inc | Formulaciones de 15-hidroxiestearato de macrogol |
US20130029919A1 (en) * | 2011-07-26 | 2013-01-31 | Allergan, Inc. | Two part formulation system for opthalmic delivery |
EA201491062A1 (ru) * | 2011-11-30 | 2014-10-30 | Ксиджен Инфлэммэйшн Лтд. | Применение обладающих способностью проникать в клетку пептидных ингибиторов пути трансдукции сигнала jnk для лечения синдрома сухости глаз |
WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
US9827250B2 (en) * | 2012-07-31 | 2017-11-28 | Johnson & Johnson Vision Care, Inc. | Lens incorporating myopia control optics and muscarinic agents |
WO2014031857A2 (en) | 2012-08-22 | 2014-02-27 | Tearscience, Inc. | Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices |
US9763827B2 (en) | 2013-04-30 | 2017-09-19 | Tear Film Innovations, Inc. | Systems and methods for the treatment of eye conditions |
ES2942724T3 (es) | 2013-04-30 | 2023-06-06 | Alcon Inc | Sistemas para el tratamiento de enfermedades del ojo |
WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
US10624948B2 (en) | 2013-06-26 | 2020-04-21 | Xigen Inflammation Ltd. | Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases |
WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
US9982027B2 (en) | 2013-10-22 | 2018-05-29 | Lubris Llc | Control of rheological properties of mixed hyaluronate/lubricin solutions |
US9668916B2 (en) | 2013-11-04 | 2017-06-06 | Vance M. Thompson | Conjunctival cover and methods therefor |
US20150141328A1 (en) * | 2013-11-18 | 2015-05-21 | The Schepens Eye Research Institute | Stimulation of human meibomian gland function |
AU2014354859B2 (en) | 2013-11-26 | 2020-04-09 | Lubris Llc | Compositions and methods for inhibiting intercellular interactions |
CN107073031B (zh) | 2014-06-15 | 2021-08-24 | 耶达研究及发展有限公司 | 利用水溶性聚合物和脂质/脂质体的表面处理 |
IL234929B (en) * | 2014-10-01 | 2021-01-31 | Yeda Res & Dev | Preparations containing liposomes and their use to prevent infections |
US9395557B2 (en) | 2014-11-12 | 2016-07-19 | Vance M. Thompson | Partial corneal conjunctival contact lens |
JP6758299B2 (ja) | 2015-01-26 | 2020-09-23 | ルブリス,エルエルシー. | 抗炎症剤としてのprg4の使用 |
US9869883B2 (en) | 2015-03-11 | 2018-01-16 | Vance M. Thompson | Tear shaping for refractive correction |
MX2017012708A (es) * | 2015-04-03 | 2018-01-09 | Santen Pharmaceutical Co Ltd | Agente terapeutico para ojo seco que comprende nandrolona o ester del mismo o metenolona o ester del mismo como un ingrediente activo. |
DK3300482T3 (da) | 2015-05-19 | 2021-10-18 | Lubris Llc | Brug af prg4 til at forbedre dynamisk synsstyrke og højere ordens aberrationer |
JP6718608B2 (ja) * | 2016-05-25 | 2020-07-08 | 国立大学法人愛媛大学 | 眼表面・眼瞼摩擦係数測定装置および眼表面・眼瞼摩擦係数評価方法 |
US10974063B2 (en) | 2016-06-30 | 2021-04-13 | Alcon Inc. | Light therapy for eyelash growth |
US10353220B2 (en) | 2016-10-17 | 2019-07-16 | Vance M. Thompson | Tear shaping for refractive correction |
US10678067B2 (en) | 2018-04-06 | 2020-06-09 | Vance M. Thompson | Tear shaping for refractive correction |
CA3104296A1 (en) * | 2018-06-21 | 2019-12-26 | Lubris, Llc | Lubricin for use in wound healing |
WO2020097345A1 (en) * | 2018-11-08 | 2020-05-14 | The Schepens Eye Research Institute, Inc. | Therapeutic approaches for tissue reconstruction and wound healing treatment |
JP2022542166A (ja) * | 2019-07-26 | 2022-09-29 | パンドラム・テクノロジーズ・プライベイト・リミテッド | バイオインク配合物、バイオプリントされた角膜レンチキュール、およびそれらの用途 |
WO2021067823A2 (en) * | 2019-10-05 | 2021-04-08 | The Schepens Eye Research Institute, Inc. | A new treatment for meibomian gland dysfunction |
US11609438B2 (en) * | 2019-10-31 | 2023-03-21 | Menicon Singapore Pte Ltd. | Ocular lens with friction control structures |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4550022A (en) * | 1981-10-05 | 1985-10-29 | Alcon Laboratories, Inc. | Tissue irrigating solution |
SE8501723L (sv) * | 1985-04-09 | 1986-10-10 | Pharmacia Ab | Preparation att anvendas vid behandling av ledinflammation |
US4964206A (en) * | 1988-03-15 | 1990-10-23 | Minnesota Mining And Manufacturing Company | Intraocular lens anchoring filament to lens element fixation method |
US4964205A (en) * | 1988-06-13 | 1990-10-23 | Rampart Packaging Inc. | Method for making screw cap jar |
US5326558A (en) | 1989-08-08 | 1994-07-05 | Genetics Institute, Inc. | Megakaryocytopoietic factor |
US6433142B1 (en) | 1989-08-08 | 2002-08-13 | Genetics Institute, Llc | Megakaryocyte stimulating factors |
RU2033165C1 (ru) | 1989-10-13 | 1995-04-20 | Межотраслевой научно-технический комплекс "Микрохирургия глаза" | Способ получения пластичного материала из коллагена |
US5688765A (en) | 1992-04-21 | 1997-11-18 | The Schepens Eye Research Institute, Inc. | Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β |
JPH07508716A (ja) | 1992-04-21 | 1995-09-28 | ザ スキーペンズ アイ リサーチ インスティテュート,インコーポレイテッド | シェーグレン症候群における眼のアンドロゲン療法 |
US6107289A (en) * | 1992-04-21 | 2000-08-22 | The Schepens Eye Research Institute, Inc. | Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β |
IL106922A (en) * | 1992-09-14 | 1998-08-16 | Novartis Ag | Complex materials with one or more wettable surfaces and a process for their preparation |
US5351100A (en) * | 1992-12-09 | 1994-09-27 | Bmc Industries, Inc. | Glass multifocal ophthalmic lens with polarizing element and method of making |
JPH09505057A (ja) | 1993-11-19 | 1997-05-20 | ザ・ユニバーシティ・オブ・シドニー | 白内障を予防または制御するための方法 |
US5515590A (en) * | 1994-07-19 | 1996-05-14 | University Of Kentucky Research Foundation | Method for reducing the generation of wear particulates from an implant |
US5518732A (en) * | 1995-02-14 | 1996-05-21 | Chiron Vision, Inc. | Bio-erodible ophthalmic shield |
EP0733918B1 (en) * | 1995-03-24 | 2003-07-30 | Ocular Research of Boston, Inc. | Hydrogel lens pre-coated with lipid layer |
RU2207885C2 (ru) * | 1995-08-30 | 2003-07-10 | Фармация Аб | Способ подачи небольшого объема лечебного раствора к целевому месту |
US6689748B1 (en) * | 1998-04-08 | 2004-02-10 | Theoharis C. Theoharides | Method of treating mast cell activation-induced diseases with a proteoglycan |
AU1521000A (en) * | 1998-11-06 | 2000-05-29 | Schepens Eye Research Institute, Inc., The | Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye |
WO2000027405A1 (fr) * | 1998-11-10 | 2000-05-18 | Denki Kagaku Kogyo Kabushiki Kaisha | Gel d'acide hyaluronique son procede de preparation et produit medical le contenant |
US6960562B2 (en) | 1999-04-23 | 2005-11-01 | Rhode Island Hospital, A Lifespan Partner | Tribonectin polypeptides and uses thereof |
US6743774B1 (en) | 1999-04-23 | 2004-06-01 | Rhode Island Hospital | Tribonectins |
EP1281722A4 (en) | 2000-02-03 | 2005-06-08 | Denki Kagaku Kogyo Kk | HYALURONIC ACID GEL, METHOD FOR THE PRODUCTION THEREOF, AND THE MEDICAL MATERIAL CONTAINING GEL |
US7026500B2 (en) * | 2000-08-24 | 2006-04-11 | University Of Tennessee Research Foundation | Halogenated selective androgen receptor modulators and methods of use thereof |
WO2002049611A2 (en) * | 2000-12-20 | 2002-06-27 | Alcon, Inc. | Ophthalmic lubricating solution adapted for use in lasik surgery |
AU2002239601B2 (en) * | 2000-12-20 | 2005-09-01 | Alcon Inc. | Intraocular irrigating solution having improved flow characteristics |
ES2261659T3 (es) | 2001-04-23 | 2006-11-16 | Nucryst Pharmaceuticals Corp. | Un medicamento o una preparacion que contiene un metal tal como plata, oro, platino o paladio como un agente antimicrobiano y su uso para el tratamiento de estados inflamatorios de la piel. |
US6815074B2 (en) | 2001-05-30 | 2004-11-09 | Novartis Ag | Polymeric materials for making contact lenses |
CN1980582B (zh) | 2001-08-17 | 2010-12-22 | 美你康株式会社 | 用于用后即弃式软隐形眼镜的包装 |
US20030134810A1 (en) | 2001-10-09 | 2003-07-17 | Chris Springate | Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents |
AR038269A1 (es) | 2002-01-09 | 2005-01-12 | Novartis Ag | Articulos polimericos que tienen un recubrimiento lubrico, y metodo para fabricarlos |
TW200304385A (en) * | 2002-03-13 | 2003-10-01 | Novartis Ag | Materials containing multiple layers of vesicles |
SE0201479D0 (sv) | 2002-05-16 | 2002-05-16 | Pharmacia Groningen Bv | Kit and method in eye surgery |
US20050196370A1 (en) | 2003-03-18 | 2005-09-08 | Zhi-Jian Yu | Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye |
US20050074497A1 (en) | 2003-04-09 | 2005-04-07 | Schultz Clyde L. | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
CA2534367A1 (en) | 2003-08-06 | 2005-02-17 | Nirmal Mulye | Pharmaceutical composition containing water soluble drug |
NZ545021A (en) * | 2003-08-14 | 2009-03-31 | Wyeth Corp | Recombinant lubricin molecules and uses thereof |
US7087237B2 (en) * | 2003-09-19 | 2006-08-08 | Advanced Ocular Systems Limited | Ocular solutions |
WO2005027933A1 (en) * | 2003-09-23 | 2005-03-31 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | Unsaturated phosphatidylcholines and uses thereof |
EP1740190A1 (de) * | 2004-03-05 | 2007-01-10 | Synthes GmbH | Verwendung eines gemisches für die herstellung eines mittels zur behandlung von defektem oder degeneriertem knorpel in vivo und bei der herstellung von natürlichem knorpelersatz in vitro |
US20090060933A1 (en) | 2004-06-14 | 2009-03-05 | Estell David A | Proteases producing an altered immunogenic response and methods of making and using the same |
US20050287223A1 (en) * | 2004-06-23 | 2005-12-29 | Peyman Gholam A | Use of amniotic membrane as biocompatible devices |
US8529889B2 (en) * | 2004-06-29 | 2013-09-10 | Massachusetts Institute Of Technology | Methods and compositions related to the modulation of intercellular junctions |
JP2008507553A (ja) * | 2004-07-23 | 2008-03-13 | ミューコサル セラピューティクス リミテッド ライアビリディ カンパニー | 粘性補給のための組成物および方法 |
US7662509B2 (en) * | 2004-10-29 | 2010-02-16 | Medtronic, Inc. | Lithium-ion battery |
EP1858522A4 (en) * | 2005-03-02 | 2008-07-16 | Pharmaceutical Inc Nascent | PHARMACEUTICALLY ACCEPTABLE CARRIER FOR OPHTHALMIC COMPOSITIONS |
CA2609053C (en) * | 2005-05-17 | 2017-04-25 | Sarcode Corporation | Compositions and methods for treatment of eye disorders |
US20080213274A1 (en) | 2005-10-28 | 2008-09-04 | Sabbadini Roger A | Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye |
JP5549045B2 (ja) * | 2006-01-13 | 2014-07-16 | 大正製薬株式会社 | 蒸発亢進型ドライアイの予防又は改善用水性点眼剤 |
US20080094573A1 (en) * | 2006-04-04 | 2008-04-24 | Vermette Patrick | Surface-modified materials, such as contact lenses, methods and kits for their preparation, and uses thereof |
US9539202B2 (en) * | 2006-04-28 | 2017-01-10 | Universidad Complutense De Madrid | Formulation of liposomal vesicles in aqueous solutions with lachrymal film characteristics |
US20070264226A1 (en) | 2006-05-10 | 2007-11-15 | Karagoezian Hampar L | Synergistically enhanced disinfecting solutions |
WO2008024456A2 (en) * | 2006-08-24 | 2008-02-28 | University Of Tennessee Research Foundation | Substituted acylanilides and methods of use thereof |
US20080097606A1 (en) | 2006-10-19 | 2008-04-24 | Cragg Andrew H | Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis |
US20080197324A1 (en) | 2007-02-20 | 2008-08-21 | Fang Zhao | Ophthalmic composition containing a polyol-acid copolymer |
US20090068247A1 (en) | 2007-09-12 | 2009-03-12 | Mucosal Therapeutics | Biocompatible devices coated with a tribonectin and methods for their production |
EP2238480B1 (en) | 2007-12-20 | 2012-02-01 | Novartis AG | Method for making contact lenses |
US8506944B2 (en) | 2008-05-07 | 2013-08-13 | The Regents Of The University Of California | Replenishment and enrichment of ocular surface lubrication |
RU2510274C2 (ru) | 2008-05-07 | 2014-03-27 | Дзе Реджентс Оф Дзе Юниверсити Оф Калифорния | Терапевтическое восстановление и усиление увлажнения поверхности глаза |
-
2009
- 2009-04-08 RU RU2010147935/15A patent/RU2510274C2/ru active
- 2009-04-08 CA CA2722913A patent/CA2722913C/en active Active
- 2009-04-08 JP JP2011508534A patent/JP5508398B2/ja active Active
- 2009-04-08 PT PT151516341T patent/PT2915529T/pt unknown
- 2009-04-08 PT PT97432041T patent/PT2285364E/pt unknown
- 2009-04-08 DK DK09743204.1T patent/DK2285364T3/en active
- 2009-04-08 WO PCT/US2009/039887 patent/WO2009137217A2/en active Application Filing
- 2009-04-08 CN CN200980126381.5A patent/CN102164593B/zh active Active
- 2009-04-08 LT LTEP15151634.1T patent/LT2915529T/lt unknown
- 2009-04-08 PL PL09743204T patent/PL2285364T3/pl unknown
- 2009-04-08 EP EP09743204.1A patent/EP2285364B1/en active Active
- 2009-04-08 ES ES09743204T patent/ES2530723T3/es active Active
- 2009-04-08 CN CN201610003437.XA patent/CN105664136A/zh active Pending
- 2009-04-08 HU HUE09743204A patent/HUE024146T2/en unknown
- 2009-04-08 PL PL15151634T patent/PL2915529T3/pl unknown
- 2009-04-08 EP EP15151634.1A patent/EP2915529B1/en active Active
- 2009-04-08 DK DK15151634.1T patent/DK2915529T3/en active
- 2009-04-08 ES ES15151634.1T patent/ES2633792T3/es active Active
- 2009-04-08 SI SI200931699T patent/SI2915529T1/sl unknown
- 2009-04-08 SI SI200931129T patent/SI2285364T1/sl unknown
- 2009-05-06 CA CA2722944A patent/CA2722944A1/en not_active Abandoned
- 2009-05-06 SI SI200932001T patent/SI2276496T1/sl unknown
- 2009-05-06 EP EP09743589.5A patent/EP2276497B1/en active Active
- 2009-05-06 ES ES09743588T patent/ES2748139T3/es active Active
- 2009-05-06 DK DK09743588.7T patent/DK2276496T3/da active
- 2009-05-06 EP EP09743588.7A patent/EP2276496B1/en active Active
- 2009-05-06 JP JP2011508633A patent/JP5439652B2/ja active Active
- 2009-05-06 JP JP2011508634A patent/JP5474054B2/ja active Active
- 2009-05-06 WO PCT/US2009/043018 patent/WO2009137603A1/en active Application Filing
- 2009-05-06 LT LT09743588T patent/LT2276496T/lt unknown
- 2009-05-06 HU HUE09743588A patent/HUE045686T2/hu unknown
- 2009-05-06 CA CA2723144A patent/CA2723144C/en active Active
- 2009-05-06 PL PL09743588T patent/PL2276496T3/pl unknown
- 2009-05-06 WO PCT/US2009/043015 patent/WO2009137602A1/en active Application Filing
-
2010
- 2010-11-05 US US12/940,370 patent/US9393285B2/en active Active
- 2010-11-05 US US12/940,454 patent/US8563028B2/en active Active
- 2010-11-05 US US12/940,425 patent/US9138457B2/en active Active
-
2013
- 2013-09-20 US US14/032,233 patent/US8945604B2/en active Active
-
2014
- 2014-05-08 US US14/272,634 patent/US9248161B2/en active Active
-
2015
- 2015-01-26 HR HRP20150097AT patent/HRP20150097T1/hr unknown
- 2015-08-20 US US14/831,317 patent/US9421241B2/en active Active
- 2015-12-18 US US14/974,055 patent/US9585936B2/en active Active
-
2016
- 2016-04-06 US US15/091,665 patent/US9730978B2/en active Active
-
2017
- 2017-07-10 US US15/645,561 patent/US20180028598A1/en not_active Abandoned
- 2017-07-13 HR HRP20171079TT patent/HRP20171079T1/hr unknown
- 2017-07-14 CY CY20171100751T patent/CY1119122T1/el unknown
-
2019
- 2019-09-25 HR HRP20191732 patent/HRP20191732T1/hr unknown
- 2019-10-03 CY CY20191101037T patent/CY1122638T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20191732T1 (hr) | Terapijska modulacija lubrikacije okularne površine | |
JP2013543862A (ja) | 眼科用緩衝組成物およびその使用方法 | |
RU2470662C2 (ru) | Способы и композиции для лечения сухости глаз | |
ES2841434T3 (es) | Lagrimas artificiales que comprenden hialuronato de sodio y carboximetilcelulosa | |
KR102268536B1 (ko) | 드라이아이 치료용 점안제 | |
US20210315805A1 (en) | Ketorolac compositions for corneal wound healing | |
CA1112573A (en) | Solution of tranexamic acid | |
Lemp | Management of the dry-eye patient | |
CA2806973A1 (en) | Preservative free bimatoprost solutions | |
EP1408929B1 (en) | Ophthalmic composition containing n-acetylcysteine for the treatment of dry-eye syndrom | |
ES2893304T3 (es) | Uso de PRG4 para mejorar la agudeza visual dinámica y aberraciones de orden superior | |
WO2005097157A1 (en) | Ophthalmic preparation containing glycomacropeptide | |
US20180344696A1 (en) | Synergistic combination of pyrrolidone carboxylic acid and/or salts thereof and hyaluronic acid and/or salts thereof, for use in the treatment and/or prevention of dryness and irritation of the mucosae, and related pharmaceutical formulations | |
JP2018515534A5 (hr) | ||
ES2754449T3 (es) | Acido carboxílico de pirrolidona (pca) para uso oftálmico | |
US20130101575A1 (en) | Lactoferrin seqences, compositions and methods for corneal wound treatment | |
KR20080077585A (ko) | 안과질환 예방 및 치료용 점안제 조성물 | |
BRPI1100191A2 (pt) | gel aquoso para aplicaÇço oftÁlmica |